{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T14:10:25Z","timestamp":1764079825214,"version":"3.44.0"},"reference-count":26,"publisher":"The Pediatric Pharmacy Association","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>Limited studies describe acute kidney injury (AKI) in children receiving trimethoprimsulfamethoxazole (SXT). The primary objective of this study was to describe AKI with SXT use in pediatric patients. Secondary objectives included describing the incidence of hyperkalemia and blood dyscrasias with SXT use.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS<\/jats:title>\n                  <jats:p>In this retrospective, single-center observational study, inpatient electronic medical records were reviewed for patients younger than 18 years of age who received at least 5 days of SXT for treatment of a bacterial infection. Patients were excluded if serum creatinine data prior to and after initiation of SXT were unavailable, they had AKI or were on hemodialysis prior to SXT initiation, or they were admitted to an oncology unit.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>Of 98 patients who met inclusion criteria, 24 (24.5%) experienced stage I AKI and 16 (16.3%) experienced stage II or III AKI. The mean treatment duration with SXT at time of AKI development was 5.9 days. Coadministration of SXT with other nephrotoxic medications increased the risk of development of AKI (OR, 1.7; 95% CI, 1.2\u20132.4). Hyperkalemia was noted in 29 patients (29.6%), anemia in 39 patients (39.8%), thrombocytopenia in 30 (30.6%), and neutropenia in 39 (39.8%).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>Changes in renal function suggestive of AKI occur frequently in pediatric patients receiving at least 5 days of treatment with SXT, particularly when using serum creatinine as a marker of AKI. In contrast, when using urine output rather than serum creatinine, the incidence is much lower and may be more reflective of a true change in renal function. Coadministration of nephrotoxic agents increases the risk of development of AKI. Anemia and hyperkalemia are common in patients receiving SXT and not associated with development of AKI. Further prospective study is warranted to validate these results.<\/jats:p>\n               <\/jats:sec>","DOI":"10.5863\/1551-6776-27.7.663","type":"journal-article","created":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T22:24:24Z","timestamp":1664231064000},"page":"663-668","source":"Crossref","is-referenced-by-count":2,"title":["Renal Impairment Associated With Trimethoprim-Sulfamethoxazole Use in the Pediatric Population"],"prefix":"10.5863","volume":"27","author":[{"given":"Caroline M.","family":"Sierra","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice (CS), Loma Linda University School of Pharmacy, Loma Linda University, Loma Linda, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yen","family":"Tran","sequence":"additional","affiliation":[{"name":"CVS Pharmacy (YT), Corona, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lacey","family":"Oana","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Riverside Medical Center Inpatient Pharmacy (LO), Riverside, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khaled","family":"Bahjri","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical and Administrative Sciences (KB), Loma Linda University School of Pharmacy, Loma Linda, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3883","published-online":{"date-parts":[[2022,9,26]]},"reference":[{"issue":"6","key":"2022092717430044800_i2331-348X-27-7-663-b1","doi-asserted-by":"crossref","first-page":"405","DOI":"10.2165\/00003495-198223060-00001","article-title":"Trimethoprim: a review of its antibacterial activity, pharmacokinetics and therapeutic use in urinary tract infections","volume":"23","author":"Brogden","year":"1982","journal-title":"Drugs"},{"issue":"4","key":"2022092717430044800_i2331-348X-27-7-663-b2","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1001\/archinte.163.4.402","article-title":"Trimethoprimsulfamethoxazole revisited","volume":"163","author":"Masters","year":"2003","journal-title":"Arch Intern Med"},{"issue":"3","key":"2022092717430044800_i2331-348X-27-7-663-b3","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/MPH.0000000000000771","article-title":"Guidelines for the prophylaxis of Pneumocystis jirovecii Pneumonia (PJP) in children with solid tumors","volume":"39","author":"Proudfoot","year":"2017","journal-title":"J Pediatr Hematol Oncol"},{"issue":"2","key":"2022092717430044800_i2331-348X-27-7-663-b4","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/MPG.0000000000002036","article-title":"Management of paediatric ulcerative colitis, part 2: acute severe colitis-an evidence-based consensus guideline from the European Crohn's and Colitis Organization and the European Society of Paediatric Gastroenterology, Hepatology and Nutrition","volume":"67","author":"Turner","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"7","key":"2022092717430044800_i2331-348X-27-7-663-b5","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1093\/cid\/cir531","article-title":"The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America","volume":"53","author":"Bradley","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"3","key":"2022092717430044800_i2331-348X-27-7-663-b6","first-page":"57","article-title":"Drug-induced renal disorders","volume":"4","author":"Shahrbaf","year":"2015","journal-title":"J Renal Inj Prev"},{"issue":"6","key":"2022092717430044800_i2331-348X-27-7-663-b7","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/S0022-5347(17)67149-0","article-title":"Effect of trimethoprim-sulfamethoxazole on the renal excretion of creatinine in man","volume":"114","author":"Berglund","year":"1975","journal-title":"J Urol"},{"key":"2022092717430044800_i2331-348X-27-7-663-b8","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.13679","article-title":"Impact of trimethoprim on serum creatinine, sodium, and potassium concentrations in patients taking trimethoprimsulfamethoxazole without changes in glomerular filtration rate [published online ahead of print May 11, 2022]","volume-title":"J Clin Pharm Ther","author":"Yokoyama"},{"issue":"7800","key":"2022092717430044800_i2331-348X-27-7-663-b9","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S0140-6736(73)90251-1","article-title":"Deterioration in renal function in association with co-trimoxazole therapy","volume":"1","author":"Kalowski","year":"1973","journal-title":"Lancet"},{"issue":"8058","key":"2022092717430044800_i2331-348X-27-7-663-b10","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S0140-6736(78)90486-5","article-title":"Effect of cotrimoxazole on normal creatinine clearance","volume":"1","author":"Shouval","year":"1978","journal-title":"Lancet"},{"key":"2022092717430044800_i2331-348X-27-7-663-b11","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1186\/cc5713","article-title":"Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury","volume":"11","author":"Mehta","year":"2007","journal-title":"Crit Care"},{"issue":"5","key":"2022092717430044800_i2331-348X-27-7-663-b12","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1093\/jac\/dks030","article-title":"Acute kidney injury associated with trimethoprim\/sulfamethoxazole","volume":"67","author":"Fraser","year":"2012","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"2022092717430044800_i2331-348X-27-7-663-b13","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000237984","article-title":"Effect of co-trimoxazole on the glomerular filtration rate of healthy adults","volume":"27","author":"Kainer","year":"1981","journal-title":"Chemotherapy"},{"issue":"1","key":"2022092717430044800_i2331-348X-27-7-663-b14","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/00007691-198204000-00011","article-title":"Effect of co-trimoxazole and sulfamethoxazole on serum creatinine in normal subjects","volume":"4","author":"Roy","year":"1982","journal-title":"Ther Drug Monit"},{"key":"2022092717430044800_i2331-348X-27-7-663-b15","doi-asserted-by":"crossref","first-page":"k341","DOI":"10.1136\/bmj.k341","article-title":"Trimethoprim use for urinary tract infection and risk of adverse outcomes in older patients: cohort study","volume":"360","author":"Crellin","year":"2018","journal-title":"BMJ"},{"issue":"4","key":"2022092717430044800_i2331-348X-27-7-663-b16","doi-asserted-by":"crossref","first-page":"c179","DOI":"10.1159\/000339789","article-title":"KDIGO clinical practice guidelines for acute kidney injury","volume":"120","author":"Khwaja","year":"2012","journal-title":"Nephron Clin Pract"},{"key":"2022092717430044800_i2331-348X-27-7-663-b17","doi-asserted-by":"crossref","first-page":"c187","DOI":"10.1159\/000328911","article-title":"Trimethoprim, creatinine, and creatinine-based equations","volume":"119","author":"Delanaye","year":"2011","journal-title":"Nephron Clin Pract"},{"key":"2022092717430044800_i2331-348X-27-7-663-b18","doi-asserted-by":"crossref","first-page":"565","DOI":"10.3389\/fped.2019.00565","article-title":"Urine output in acute kidney injury: the cheapest and most impactful biomarker","volume":"7","author":"Goldstein","year":"2019","journal-title":"Front Pediatr"},{"issue":"4","key":"2022092717430044800_i2331-348X-27-7-663-b19","doi-asserted-by":"crossref","first-page":"856","DOI":"10.2215\/CJN.08110910","article-title":"Acute kidney injury and increasing nephrotoxic-medication exposure in noncritically-ill children","volume":"6","author":"Moffett","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"issue":"12","key":"2022092717430044800_i2331-348X-27-7-663-b20","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1177\/1060028013509973","article-title":"An evaluation of hyperkalemia and serum creatinine elevation associated with different dosage levels of outpatient trimethoprim-sulfamethoxazole with and without concomitant medications","volume":"47","author":"Gentry","year":"2013","journal-title":"Ann Pharmacother"},{"issue":"9","key":"2022092717430044800_i2331-348X-27-7-663-b21","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1177\/1060028020909539","article-title":"Dose-dependent hyperkalemia among hospitalized, HIV-infected patients receiving sulfamethoxazole\/trimethoprim","volume":"54","author":"Caulder","year":"2020","journal-title":"Ann Pharmacother"},{"issue":"2","key":"2022092717430044800_i2331-348X-27-7-663-b22","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1093\/clinids\/4.2.429","article-title":"Adverse reactions to trimethoprim-sulfamethoxazole","volume":"4","author":"Lawson","year":"1982","journal-title":"Rev Infect Dis"},{"issue":"4","key":"2022092717430044800_i2331-348X-27-7-663-b23","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/j.1365-2796.1990.tb00245.x","article-title":"Trimethoprim-sulphamethoxazole-associated blood dyscrasias. Ten years' experience of the Swedish spontaneous reporting system","volume":"228","author":"Keisu","year":"1990","journal-title":"J Intern Med"},{"issue":"11","key":"2022092717430044800_i2331-348X-27-7-663-b24","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1097\/00006454-199711000-00005","article-title":"Adverse reactions to trimethoprim-sulfamethoxazole among children with human immunodeficiency virus infection","volume":"16","author":"Rieder","year":"1997","journal-title":"Pediatr Infect Dis J"},{"issue":"12","key":"2022092717430044800_i2331-348X-27-7-663-b25","first-page":"1100","article-title":"Hematologic abnormalities after oral trimethoprim-sulfamethoxazole therapy in children","volume":"135","author":"Asmar","year":"1981","journal-title":"Am J Dis Child"},{"issue":"6","key":"2022092717430044800_i2331-348X-27-7-663-b26","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0022-3476(85)80257-2","article-title":"Similar hemato-logic changes in children receiving trimethoprim-sulfamethoxazole or amoxicillin for otitis media","volume":"106","author":"Feldman","year":"1985","journal-title":"J Pediatr"}],"container-title":["The Journal of Pediatric Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/meridian.allenpress.com\/jppt\/article-pdf\/27\/7\/663\/3124355\/i2331-348x-27-7-663.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/meridian.allenpress.com\/jppt\/article-pdf\/27\/7\/663\/3124355\/i2331-348x-27-7-663.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T18:30:00Z","timestamp":1738780200000},"score":1,"resource":{"primary":{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/27\/7\/article-p663.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,1]]},"references-count":26,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,9,26]]},"published-print":{"date-parts":[[2022,9,1]]}},"URL":"https:\/\/doi.org\/10.5863\/1551-6776-27.7.663","relation":{},"ISSN":["2331-348X","1551-6776"],"issn-type":[{"type":"electronic","value":"2331-348X"},{"type":"print","value":"1551-6776"}],"subject":[],"published":{"date-parts":[[2022,9,1]]}}}